First-in-World Trial Tests Subcutaneous Blinatumomab for Rare Mixed-Phenotype Acute Leukemia
West Virginia University Cancer Institute has dosed the first patient in a phase 1/2 trial evaluating subcutaneous blinatumomab for CD19-positive mixed-phenotype acute leukemia, a rare disease with no FDA-approved therapies. The first patient achieved complete remission after one cycle.